Skip to content

Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment

Comparing the Performance of Automated Breast Ultrasonography (ABUS) to Hand-Held Breast Ultrasonography (WBUS) in Breast Cancer Treatment Response Assessment in a Tertiary Cancer Center: A Prospective Study

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05005936
Enrollment
0
Registered
2021-08-16
Start date
2021-11-29
Completion date
2021-11-29
Last updated
2022-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Carcinoma

Brief summary

This study compares the performance of automated breast ultrasonography and conventional hand-held whole breast ultrasonography when checking for response to breast cancer treatment. Breast ultrasonography is operator dependent and time-intensive. Automated breast ultrasonography scanners were developed to allow standardization of ultrasound scanning and scanning to be performed by any technologist, with or without previous ultrasound experience, without physician involvement. This study may validate the use of the automated breast ultrasonography.

Detailed description

PRIMARY OBJECTIVE: I. To estimate and compare the accuracy of automated breast ultrasonography (ABUS) and hand-held whole breast ultrasonography (WBUS) in predicting pathology complete response (pCR) with relative tumor volume change, using the receiver operating characteristic (ROC) curve analysis. SECONDARY OBJECTIVES: I. To evaluate the reproducibility of tumor volume measurements obtained by ABUS and handheld WBUS, respectively, using data collected at baseline for initial staging. II. To assess the agreement in relative tumor volume change (RC) (end-of-treatment versus \[vs.\] pre-treatment) between ABUS and WBUS. III. To estimate and compare the following diagnostic measures for ABUS and WBUS: sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). OUTLINE: Patients undergo ABUS over 15 minutes followed by WBUS over 30 minutes at baseline, mid-treatment and pre-surgery (end of treatment).

Interventions

PROCEDUREUltrasonography

Undergo ABUS

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The subjects to be studied will include patients seen in MD Anderson Breast imaging clinic at the Texas Medical Center (TMC) * With breast cancer or suspicion of breast cancer * Male or female who is older than 18 years of age * Of any race * Who consent to obtain technologist performed breast ultrasound and automated breast ultrasound * English and non-English speakers (with language interpreter to assist in translation for non-English speakers)

Exclusion criteria

* Patient who is less than 18 years of age * Imaging obtained outside of MD Anderson TMC * Surgery pathology from outside of MD Anderson will be excluded from this study

Design outcomes

Primary

MeasureTime frameDescription
Area under the receiver operating characteristic (ROC) curvethrough study completion, an average of 1 yearWill compute relative tumor volume change for both automated breast ultrasonography (ABUS) and hand-held whole breast ultrasonography (WBUS) and estimate pathology complete response ROC curves for each. Will estimate the areas under the ROC curves along with 95% confidence intervals and then compare the values statistically.

Secondary

MeasureTime frameDescription
Relative tumor volume changethrough study completion, an average of 1 yearWill compute the relative change in tumor volume for ABUS and WBUS and assess their agreement using the Bland-Altman approach.
Sensitivitythrough study completion, an average of 1 yearThe cutoff point will be determined using Youden Index, i.e., the point that maximize (sensitivity specificity).
Tumor volumethrough study completion, an average of 1 yearWill compute the intraclass correlation coefficient for each method along with 95% confidence intervals and then compare these estimates.
Positive predictive valuethrough study completion, an average of 1 year
Negative predictive valuethrough study completion, an average of 1 year
Specificitythrough study completion, an average of 1 yearThe cutoff point will be determined using Youden Index, i.e., the point that maximize (sensitivity specificity).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026